Strides Pharma sells its Singapore manufacturing site for $15 million

This sale will also help Strides to reduce annual costs by Rs 75 crore, of which Rs 18 crore will be reduction in operating expenses and Rs 57 crore in depreciation and operating lease expenses. Strides said the Transaction would be EPS (earnings per share) accretive with no impact on revenues.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KvRm58k
via IFTTT